Form 4: Serina Therapeutics Director Acquires Convertible Preferred Stock

Gregory Bailey, a director of Serina Therapeutics, acquired 762,548 shares of Series A Convertible Preferred Stock on April 8, 2025.

Summary

• On April 8, 2025, Gregory Bailey, a director of Serina Therapeutics, acquired 762,548 shares of Series A Convertible Preferred Stock.
• The transaction was reported on April 10, 2025.
• The Series A Convertible Preferred Stock has a conversion price of $5.18 and is convertible into 762,548 shares of common stock.
• The Series A Convertible Preferred Stock is perpetual and has no expiration date.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of a transaction. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such filings can provide insights into management's confidence in the company's prospects.

Stakeholder Impact

• The acquisition of preferred stock by a director could signal confidence in the company's future, potentially impacting shareholder sentiment positively.

Key Dates

Keywords

Form 4, Beneficial Ownership, Gregory Bailey, Serina Therapeutics, Convertible Preferred Stock, Director